Eli Lilly has opted to end a phase 2 rheumatoid arthritis (RA) trial of a drug it is developing with Korea’s Hanmi Pharmaceuticals, according to press reports. The Korea Biomedical Review cited ...

Roche’s Genentech unit is to partner with South Korea’s Hanmi Pharmaceutical, to develop and market a phase 1 cancer drug, in a deal potentially worth over $900 million. Under the agreement ...

Hanmi Pharmaceutical CEO Park Jae-hyun at the extraordinary shareholder meeting held in Songpa District, southern Seoul, on Thursday. [YONHAP] Efforts to seize the management rights of Hanmi ...